The Raffles Dialogue on Human Wellbeing and Security

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15260%2F16%3A33160579" target="_blank" >RIV/61989592:15260/16:33160579 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S2214109X15002843" target="_blank" >http://www.sciencedirect.com/science/article/pii/S2214109X15002843</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2214-109X(15)00284-3" target="_blank" >10.1016/S2214-109X(15)00284-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Raffles Dialogue on Human Wellbeing and Security

Popis výsledku v původním jazyce

Tikki Pang and colleagues emphasize that "we must find the right balance between the roles of government and markets so that all those in need can access affordable medicine and health care". Probably the biggest imbalance between role of government and market is in drug discovery and development. There is almost no way how to finance large clinical trials of old, unpatentable drugs repurposed for treatment of deadly diseases. It has been the case of phase III clinical trials of an old antibiotic paromomycin for visceral leishmaniasis funded by Bill and Melinda Gates Foundations, the World Health Organization and other institutions, but not governments. At the same time, such clinical trials may lead to very efficient and low-cost drugs developed in the public interest. The cost of paromomycin is EUR4.19 for a 21-day course for a 35 kg patient.

Název v anglickém jazyce

The Raffles Dialogue on Human Wellbeing and Security

Popis výsledku anglicky

Tikki Pang and colleagues emphasize that "we must find the right balance between the roles of government and markets so that all those in need can access affordable medicine and health care". Probably the biggest imbalance between role of government and market is in drug discovery and development. There is almost no way how to finance large clinical trials of old, unpatentable drugs repurposed for treatment of deadly diseases. It has been the case of phase III clinical trials of an old antibiotic paromomycin for visceral leishmaniasis funded by Bill and Melinda Gates Foundations, the World Health Organization and other institutions, but not governments. At the same time, such clinical trials may lead to very efficient and low-cost drugs developed in the public interest. The cost of paromomycin is EUR4.19 for a 21-day course for a 35 kg patient.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FQ - Veřejné zdravotnictví, sociální lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet Global Health

ISSN

2214-109X

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

1

Strana od-do

92

Kód UT WoS článku

000368619500013

EID výsledku v databázi Scopus

2-s2.0-84957537366